Loading
A phase 1 trial of FID-007 run by University of Southern California, active and no longer recruiting.
FID-007 in Treating Participants With Advanced Solid Tumors is a phase 1 interventional study registered as NCT03537690 by University of Southern California, with 50 participants planned, started 2018-05-25. Conditions recorded: Advanced Malignant Solid Neoplasm and Refractory Malignant Solid Neoplasm. Interventions recorded: Laboratory Biomarker Analysis, PEOX-based Polymer Encapsulated Paclitaxel FID-007 and Pharmacokinetic Study.
Shares FID-007, Fulgent Genetics and the tag pipeline.
Shares FID-007, Fulgent Genetics and the tag pipeline.
Shares Fulgent Genetics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulgent Genetics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/